BlackRock Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

BlackRock Investment Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.92M	Sell	59,673 -94	-0.2%	-$4.01K	﹤0.01%	2241
2016 Q3	$2.99M	Sell	59,767 -187	-0.3%	-$7.76K	﹤0.01%	1859
2016 Q2	$2.54M	Buy	59,954 +8,922	+17%	+$486K	﹤0.01%	1923
2016 Q1	$3.36M	Buy	51,032 +2,901	+6%	+$151K	﹤0.01%	1643
2015 Q4	$2.99M	Buy	48,131 +897	+2%	+$63.1K	﹤0.01%	1786
2015 Q3	$3.16M	Sell	47,234 -524	-1%	-$42.8K	﹤0.01%	1707
2015 Q2	$4.65M	Buy	47,758 +12,956	+37%	+$1.23M	0.01%	1558
2015 Q1	$3.25M	Buy	34,802 +564	+2%	+$48K	﹤0.01%	1691
2014 Q4	$3.04M	Sell	34,238 -304	-0.9%	-$22.1K	﹤0.01%	1726
2014 Q3	$2.39M	Buy	34,542 +46	+0.1%	+$2.46K	﹤0.01%	1870
2014 Q2	$1.98M	Buy	34,496 +401	+1%	+$20.4K	﹤0.01%	2076
2014 Q1	$1.35M	Buy	34,095 +131	+0.4%	+$5.61K	﹤0.01%	2296
2013 Q4	$1.43M	Sell	33,964 -607	-2%	-$17.6K	﹤0.01%	2258
2013 Q3	$1.03M	Buy	34,571 +4,546	+15%	+$159K	﹤0.01%	2418
2013 Q2	$1.59M	Buy	+30,025	New	+$1.32M	﹤0.01%	2027

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's MACK Position: Q4 2016 in Review

BlackRock Investment Management reduced its Merrimack Pharmaceuticals, Inc. (MACK) stake by 0.16% in Q4 2016, selling an estimated $4.01K and leaving 59,673 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

BlackRock Investment Management first reported a position in MACK in Q2 2013 and has held it in 15 quarters since. The position peaked at $4.65M in Q2 2015. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

BlackRock Investment Management held 59,673 shares of Merrimack Pharmaceuticals, Inc. worth $1.92M as of Q4 2016.
BlackRock Investment Management sold 94 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $4.01K.
Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2241 holding.
BlackRock Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $4.65M in Q2 2015.
136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.